New hope for kids with tough lymphoma: global trial launches

NCT ID NCT05991388

Recruiting now Disease control Sponsor: University of Birmingham Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is for children and young people with B-cell Non-Hodgkin lymphoma that has come back or not responded to treatment. Current treatments are harsh and only work for about 30 out of 100 children. The trial will test several new medicines, alone or with chemotherapy, to see if they are safer and more effective. Participants will be monitored for at least two years after treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-CELL NON-HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell neoplasm B-cell non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

B-CELL NON-HODGKIN LYMPHOMA

Contacts and locations

Locations

Birmingham Children's Hospital
RECRUITING

Birmingham, United Kingdom
Bristol Royal Hospital for Children
RECRUITING

Bristol, United Kingdom
Perth Children's Hospital
RECRUITING

Perth, Washington, Australia
Princess Máxima Centre for Pediatric Oncology
RECRUITING

Utrecht, Netherlands
Queensland Children's Hospital
NOT_YET_RECRUITING

Brisbane, Queensland, Australia
Royal Manchester Children's Hospital
RECRUITING

Manchester, United Kingdom
Sahlgrenska University Hospital
NOT_YET_RECRUITING

Gothenburg, Sweden
St. Anna Children's Hospital
RECRUITING

Vienna, Austria
Starship Children's Hospital
NOT_YET_RECRUITING

Auckland, New Zealand
The Children's Hospital at Westmead
NOT_YET_RECRUITING

Sydney, New South Wales, Australia
UZ Leuven
NOT_YET_RECRUITING

Leuven, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.